{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:24:55Z","timestamp":1780424695864,"version":"3.54.1"},"reference-count":137,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi260105-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Alzheimer disease (AD) disproportionately affects racial and ethnic populations underrepresented in US clinical research, raising concerns about the generalizability of AD trial findings and the evaluation of treatment safety and efficacy for populations most affected by AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260105-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine patterns and trends in the reporting and representation of patient race and ethnicity in US-based phase 3 AD clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260105-6\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>This systematic review examined US-based phase 3 AD drug trials identified through the Trialtrove trial database between 1997 and 2023. Trials were cross-referenced with peer-reviewed publications, ClinicalTrials.gov, pharmaceutical company reports, and conference abstracts. Completed trials were eligible for inclusion if they were designated as phase 3 drug trials targeting AD and recruited patients exclusively in the US. Primary outcomes included reporting of race and ethnicity, the number of racial and ethnic groups reported, and their representation among trial populations. Secondary outcomes included terminology used, reporting of safety or efficacy differences by race and ethnicity, and discussion of racial and ethnic representation in trial reports. Temporal trends in reporting and representation were assessed. Methodologic quality was evaluated using the Quality Rating Scheme for Studies and Other Evidence. Data collection was completed May 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260105-7\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Among 88 US-based phase 3 AD clinical trials conducted between 1997 and 2023, 71 (80.7%) had publicly available results, including 52 (59.1%) published in peer-reviewed journals. Nearly half of published trials (35 [49.3%]) did not report patient race or ethnicity. Among published trials, reporting was inconsistent and focused predominantly on White (36 [50.7%]) patients, with substantially fewer trials reporting data on Asian or Pacific Islander (11 [15.5%]), Black (20 [28.2%]), Hispanic (13 [18.3%]), or Native American (2 [2.8%]) patients. Median (IQR) enrollment of White patients was 91.3% (87.3%-93.6%), whereas enrollment of underrepresented patient populations was markedly lower, with median (IQR) enrollment of 0.9% (0.6%-1.6%) for Asian or Pacific Islander, 4.5% (3.6%-6.6%) for Black (ethnicity unspecified), 7.2% (3.7%-9.1%) for Black (non-Hispanic), 5.2% (3.1%-6.6%) for Hispanic, and 0.4% (0%-0.8%) for Native American patients. Few trials (3 of 71 [4.2%]) conducted subgroup analyses by race or ethnicity, and none reported detailed subgroup characteristics or safety or efficacy outcomes by patient race and ethnicity. Reporting practices and representation showed little improvement over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260105-8\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>US-based phase 3 AD trials showed substantial gaps in racial and ethnic reporting and representation from 1997 to 2023, limiting the evaluation of treatment safety and efficacy across diverse populations. These findings suggest that stronger reporting standards and more inclusive trial design and recruitment strategies are needed to improve the equity and generalizability of AD trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.2427","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:30:21Z","timestamp":1774625421000},"page":"e262427","source":"Crossref","is-referenced-by-count":2,"title":["Racial and Ethnic Reporting and Representation in US Alzheimer Clinical Trials"],"prefix":"10.1001","volume":"9","author":[{"given":"Zhuoer","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Health Policy and Administration, School of Public Health, University of Illinois Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochen","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Health Care Management and Economics, The Wharton School, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kien","family":"Lau","sequence":"additional","affiliation":[{"name":"Yale College, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Stumpf","sequence":"additional","affiliation":[{"name":"Yale College, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"4","key":"zoi260105r1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70235","article-title":"2025 Alzheimer\u2019s disease facts and figures.","volume":"21","author":"Alzheimer\u2019s Association","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"12","key":"zoi260105r2","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaneurol.2022.3543","article-title":"Estimating the prevalence of dementia and mild cognitive impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol project.","volume":"79","author":"Manly","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi260105r3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamainternmed.2016.6807","article-title":"A Comparison of the prevalence of dementia in the United States in 2000 and 2012.","volume":"177","author":"Langa","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi260105r4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jamainternmed.2024.1132","article-title":"Early-life circumstances and racial disparities in cognition among older adults in the US.","volume":"184","author":"Lin","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi260105r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52713","article-title":"Exposure to school racial segregation and late-life cognitive outcomes.","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi260105r6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamainternmed.2024.3149","article-title":"Randomized clinical trials that advance health and health equity: JAMA Internal Medicine call for papers.","volume":"184","author":"Wang","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi260105r7","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12389","article-title":"A call to address structural barriers to Hispanic\/Latino representation in clinical trials on Alzheimer\u2019s disease and related dementias: a micro-meso-macro perspective.","volume":"9","author":"Aranda","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi260105r8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.trci.2016.09.004","article-title":"African Americans are less likely to enroll in preclinical Alzheimer\u2019s disease clinical trials.","volume":"3","author":"Zhou","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7","key":"zoi260105r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14606","article-title":"Inclusion of underrepresented groups in preclinical Alzheimer disease trials\u2014opportunities abound.","volume":"4","author":"Manly","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi260105r10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jamaneurol.2021.2943","article-title":"Characterizing demographic, racial, and geographic diversity in dementia research: a systematic review.","volume":"78","author":"Mooldijk","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"zoi260105r11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jama.2023.11704","article-title":"Donanemab for Alzheimer disease-who benefits and who is harmed?","volume":"330","author":"Manly","year":"2023","journal-title":"JAMA"},{"issue":"16","key":"zoi260105r12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jama.2021.15286","article-title":"Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with Medicare beneficiaries with Alzheimer disease and mild cognitive impairment.","volume":"326","author":"Anderson","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"zoi260105r13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/jama.2024.10266","article-title":"Integrating clinical trials and practice: a new JAMA series and call for papers.","volume":"332","author":"Curfman","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"zoi260105r14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-000920","article-title":"Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies.","volume":"3","author":"Miller","year":"2024","journal-title":"BMJ Med"},{"issue":"4","key":"zoi260105r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7063","article-title":"Reporting of study participant demographic characteristics and demographic representation in premarketing and postmarketing studies of novel cancer therapeutics.","volume":"4","author":"Varma","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi260105r16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13063-016-1322-4","article-title":"Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.","volume":"17","author":"Downing","year":"2016","journal-title":"Trials"},{"issue":"10","key":"zoi260105r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018.","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260105r18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14283\/jpad.2021.49","article-title":"Representation of racial and ethnic minority populations in dementia prevention trials: a systematic review.","volume":"9","author":"Shaw","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"zoi260105r19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/alz.12433","article-title":"Diversity in Alzheimer\u2019s disease drug trials: the importance of eligibility criteria.","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement"},{"key":"zoi260105r20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2018.09.012","article-title":"Representation of ethnic groups in dementia trials: systematic review and meta-analysis.","volume":"394","author":"Vyas","year":"2018","journal-title":"J Neurol Sci"},{"key":"zoi260105r21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neubiorev.2019.03.020","article-title":"Race reporting and disparities in clinical trials on Alzheimer\u2019s disease: a systematic review.","volume":"101","author":"Canevelli","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"zoi260105r22","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1002\/alz.14041","article-title":"Social determinants of health but not global genetic ancestry predict dementia prevalence in Latin America.","volume":"20","author":"Llibre-Guerra","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi260105r23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208116","article-title":"Racial and ethnic differences in the population-attributable fractions of Alzheimer disease and related dementias.","volume":"102","author":"Park","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"zoi260105r24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1080\/07317115.2025.2534651","article-title":"Decomposing racial and ethnic disparities in risk and protective factors of dementia in the U.S.","volume":"48","author":"Ferdows","year":"2025","journal-title":"Clin Gerontol"},{"issue":"5","key":"zoi260105r25","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer\u2019s disease facts and figures.","volume":"20","author":"Alzheimer\u2019s Association","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi260105r26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamainternmed.2022.5600","article-title":"Sex, racial, and ethnic representation in COVID-19 clinical trials: a systematic review and meta-analysis.","volume":"183","author":"Xiao","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi260105r28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1086\/712506","article-title":"Killer acquisitions.","volume":"129","author":"Cunningham","year":"2021","journal-title":"J Polit Econ"},{"issue":"2","key":"zoi260105r29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rfs\/hhab024","article-title":"Missing novelty in drug development.","volume":"35","author":"Krieger","year":"2022","journal-title":"Rev Financ Stud"},{"issue":"12","key":"zoi260105r30","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group.","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"zoi260105r33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archneur.63.1.49","article-title":"A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.","volume":"63","author":"Reisberg","year":"2006","journal-title":"Arch Neurol"},{"issue":"2","key":"zoi260105r34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","article-title":"A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.","volume":"21","author":"van Dyck","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"17","key":"zoi260105r35","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease: the Alzheimer\u2019s Disease Cooperative Study.","volume":"336","author":"Sano","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260105r37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000069988","article-title":"A large, community-based, open-label trial of donepezil in the treatment of Alzheimer\u2019s disease.","volume":"16","author":"Relkin","year":"2003","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"zoi260105r43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1740774508096313","article-title":"A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer\u2019s disease and loss of memory in women: design and baseline characteristics.","volume":"5","author":"Sano","year":"2008","journal-title":"Clin Trials"},{"issue":"7","key":"zoi260105r44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/sleep\/26.7.893","article-title":"A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer\u2019s disease.","volume":"26","author":"Singer","year":"2003","journal-title":"Sleep"},{"issue":"3","key":"zoi260105r50","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer\u2019s disease: Alzheimer\u2019s Disease Cooperative Study.","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"issue":"19 Pt 2","key":"zoi260105r51","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1212\/01.wnl.0000303814.13509.db","article-title":"A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline.","volume":"70","author":"Dodge","year":"2008","journal-title":"Neurology"},{"issue":"7","key":"zoi260105r55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.","volume":"16","author":"Streim","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"zoi260105r56","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting.","volume":"49","author":"Tariot","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"zoi260105r57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jamda.2008.06.006","article-title":"A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer\u2019s, vascular, or mixed dementia.","volume":"10","author":"Rappaport","year":"2009","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"zoi260105r58","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4088\/JCP.10m06708","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer\u2019s disease.","volume":"73","author":"Frakey","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"zoi260105r59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.trci.2018.09.009","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer\u2019s disease: A pilot study.","volume":"4","author":"Zhu","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"zoi260105r60","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"zoi260105r61","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/156720505774932287","article-title":"A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimers type.","volume":"2","author":"Schneider","year":"2005","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"zoi260105r62","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"zoi260105r66","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/cns.12158","article-title":"A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg\/24 h versus 4.6 mg\/24 h in severe Alzheimer\u2019s dementia.","volume":"19","author":"Farlow","year":"2013","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"zoi260105r67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jalz.2008.09.004","article-title":"Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.","volume":"5","author":"Meinert","year":"2009","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi260105r70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/gps.1459","article-title":"An open-label study of escitalopram (Lexapro) for the treatment of \u201cDepression of Alzheimer\u2019s disease\u201d (dAD).","volume":"21","author":"Rao","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"zoi260105r72","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jalz.2010.01.013","article-title":"Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline.","volume":"6","author":"Yurko-Mauro","year":"2010","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi260105r74","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"zoi260105r75","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/JGP.0b013e31818cd3a4","article-title":"Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.","volume":"16","author":"Small","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"zoi260105r76","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.","volume":"159","author":"Pollock","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"12","key":"zoi260105r77","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4088\/JCP.v65n1217","article-title":"Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.","volume":"65","author":"Mulsant","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"zoi260105r78","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/appi.ajgp.13.11.942","article-title":"Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.","volume":"13","author":"Tariot","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"issue":"17","key":"zoi260105r79","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"issue":"23","key":"zoi260105r81","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"issue":"7","key":"zoi260105r82","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2174\/156720511797633205","article-title":"Effects of galantamine in Alzheimer\u2019s disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment.","volume":"8","author":"Gaudig","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"12","key":"zoi260105r83","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch Neurol"},{"issue":"4","key":"zoi260105r84","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/01.WNL.0000134664.80320.92","article-title":"Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.","volume":"63","author":"Salloway","year":"2004","journal-title":"Neurology"},{"issue":"8","key":"zoi260105r85","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.283.8.1007","article-title":"Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial.","volume":"283","author":"Mulnard","year":"2000","journal-title":"JAMA"},{"issue":"24","key":"zoi260105r87","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1001\/jama.2009.1913","article-title":"Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial.","volume":"302","author":"Snitz","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"zoi260105r88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00002093-200201000-00004","article-title":"H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine.","volume":"16","author":"Carlson","year":"2002","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"15","key":"zoi260105r89","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA"},{"issue":"11","key":"zoi260105r90","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1212\/01.WNL.0000096376.03678.C1","article-title":"Idebenone treatment fails to slow cognitive decline in Alzheimer\u2019s disease.","volume":"61","author":"Thal","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"zoi260105r91","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2165\/00044011-200525080-00003","article-title":"Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer\u2019s disease: results of a 52-week open-label study.","volume":"25","author":"Edwards","year":"2005","journal-title":"Clin Drug Investig"},{"issue":"3","key":"zoi260105r92","doi-asserted-by":"publisher","first-page":"B9","DOI":"10.1016\/j.jamda.2007.01.050","article-title":"Long-term safety and efficacy of memantine treatment in moderate to severe Alzheimer\u2019s disease: results from a three-year trial.","volume":"8","author":"Aupperle","year":"2007","journal-title":"J Am Med Dir Assoc"},{"issue":"14","key":"zoi260105r94","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease.","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260105r95","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","article-title":"Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.","volume":"14","author":"Peskind","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"zoi260105r96","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","article-title":"Memantine treatment in patients with mild to moderate Alzheimers disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.","volume":"5","author":"Porsteinsson","year":"2008","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"zoi260105r97","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"zoi260105r98","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jalz.2007.10.013","article-title":"One-week dose titration of extended release galantamine in patients with Alzheimer\u2019s disease.","volume":"4","author":"Scharre","year":"2008","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi260105r100","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00415-006-0374-x","article-title":"Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer\u2019s disease.","volume":"254","author":"Ott","year":"2007","journal-title":"J Neurol"},{"issue":"3","key":"zoi260105r101","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.","volume":"58","author":"Doody","year":"2001","journal-title":"Arch Neurol"},{"issue":"4S_part_15","key":"zoi260105r102","doi-asserted-by":"publisher","first-page":"T493","DOI":"10.1016\/j.jalz.2008.05.1487","article-title":"P2-408: results of next day crossover study of donepezil (Aricept) to rivastigmine patch (Exelon Patch) in Alzheimer\u2019s disease patients: a two-month clinical experience.","volume":"4","author":"Shua-Haim","year":"2008","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4S_part_15","key":"zoi260105r103","doi-asserted-by":"publisher","first-page":"T493","DOI":"10.1016\/j.jalz.2008.05.1489","article-title":"P2-410: results of next day crossover study of galantamine ER (Razadyne ER) to rivastigmine patch (Exelon Patch) in Alzheimer\u2019s disease patients: a two-month clinical experience.","volume":"4","author":"Shua-Haim","year":"2008","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4S_part_14","key":"zoi260105r104","doi-asserted-by":"publisher","first-page":"P430","DOI":"10.1016\/j.jalz.2009.04.968","article-title":"P3-297: longitudinal measure of IVIG treatment effect in patients with Alzheimer\u2019s and Lewy Body disease.","volume":"5","author":"Shankle","year":"2009","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4S_part_25","key":"zoi260105r105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.09.149","article-title":"P4-454: a long-term, open-label extension study evaluating the safety of extended-release memantine (28 mg) in patients with moderate to severe Alzheimer\u2019s disease.","volume":"7","author":"Perhach","year":"2011","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"zoi260105r108","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/156720507779939805","article-title":"Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.","volume":"4","author":"Zhong","year":"2007","journal-title":"Curr Alzheimer Res"},{"issue":"7","key":"zoi260105r109","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1212\/WNL.58.7.1050","article-title":"Randomized pilot study of nimesulide treatment in Alzheimer\u2019s disease.","volume":"58","author":"Aisen","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"zoi260105r110","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","article-title":"Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer\u2019s disease.","volume":"161","author":"Cummings","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"6","key":"zoi260105r111","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jalz.2012.11.012","article-title":"Results of a follow-up study to the randomized Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial (ADAPT).","volume":"9","author":"Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial Research Group","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi260105r112","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","article-title":"Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.","volume":"14","author":"Mintzer","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"zoi260105r113","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: no effect on Alzheimer\u2019s disease in a 1-year, randomized, blinded, controlled study.","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"zoi260105r115","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/1533317514556874","article-title":"Testosterone treatment of men with mild cognitive impairment and low testosterone levels.","volume":"30","author":"Cherrier","year":"2015","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"9","key":"zoi260105r117","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","article-title":"Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.","volume":"55","author":"Teri","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"zoi260105r119","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","article-title":"Updated guidance on the reporting of race and ethnicity in medical and science journals.","volume":"326","author":"Flanagin","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"zoi260105r123","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamaneurol.2022.2274","article-title":"What should the goals be for diverse recruitment in Alzheimer clinical trials?","volume":"79","author":"Grill","year":"2022","journal-title":"JAMA Neurol"},{"issue":"15","key":"zoi260105r124","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jama.2022.3550","article-title":"Association of race and ethnicity with incidence of dementia among older adults.","volume":"327","author":"Kornblith","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"zoi260105r125","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020-2060).","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"6","key":"zoi260105r126","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13927","article-title":"Assessing strategies for inclusion of marginalized communities in clinical trials\u2014what\u2019s the plan?","volume":"7","author":"Young","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260105r127","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8739","article-title":"Barriers to clinical trial implementation among community care centers.","volume":"7","author":"Ebrahimi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi260105r128","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27073","article-title":"A protocol for the inclusion of minoritized persons in Alzheimer disease research from the ADNI3 Diversity Taskforce.","volume":"7","author":"Okonkwo","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260105r129","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/geront\/gnac060","article-title":"Assessing equitable inclusion of underrepresented older adults in Alzheimer\u2019s disease, related cognitive disorders, and aging-related research: a scoping review.","volume":"63","author":"Godbole","year":"2023","journal-title":"Gerontologist"},{"issue":"6","key":"zoi260105r130","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.14283\/jpad.2024.149","article-title":"Examining the role of community engagement in enhancing the participation of racial and ethnic minoritized communities in Alzheimer\u2019s disease clinical trials: a rapid review.","volume":"11","author":"Dabiri","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"zoi260105r131","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1377\/hlthaff.2013.1314","article-title":"Obstacles and opportunities in Alzheimer\u2019s clinical trial recruitment.","volume":"33","author":"Watson","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi260105r132","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2018.09.009","article-title":"Perspectives on ethnic and racial disparities in Alzheimer\u2019s disease and related dementias: update and areas of immediate need.","volume":"15","author":"Babulal","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi260105r133","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13195-023-01177-x","article-title":"Recruitment across two decades of NIH-funded Alzheimer\u2019s disease clinical trials.","volume":"15","author":"Ritchie","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"22","key":"zoi260105r134","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1001\/jama.2024.20493","article-title":"Representativeness of studies required under Medicare\u2019s coverage with evidence development program.","volume":"332","author":"Mooghali","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"zoi260105r135","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14364","article-title":"Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer disease trial.","volume":"4","author":"Raman","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260105r136","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70129","article-title":"A multiperspective investigation of the underrepresentation of minoritized ethnic participants in dementia research and proposed strategies to improve inclusive recruitment practices.","volume":"21","author":"Marchant","year":"2025","journal-title":"Alzheimers Dement"},{"key":"zoi260105r40","volume-title":"A Long-Term Extension Study Evaluating the Safety and Tolerability of Four Memantine Dosing Regimens in Patients With Moderate to Severe Dementia of the Alzheimer\u2019s Type - Phase D","author":"Forest Laboratories, Inc.","year":"2006"},{"key":"zoi260105r27","unstructured":"Trialtrove: the go-to resource for informing clinical trial strategy, design and execution. Citeline. Accessed September 29, 2024. https:\/\/www.citeline.com\/en\/products-services\/clinical\/trialtrove"},{"key":"zoi260105r31","unstructured":"A 12-week, open label trial of an investigational medication in the treatment of Alzheimer\u2019s disease. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/16530?qId=beb7c5ac-5632-4c1e-b0db-b0db3e08f911"},{"key":"zoi260105r32","unstructured":"A 20-month, placebo-controlled research study evaluating an investigational drug for Alzheimer\u2019s disease. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/186159?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r36","unstructured":"Conference abstract. A head to head study of donepezil, rivastigmine, and galantamine for the treatment of Alzheimer\u2019s disease. Alzheimer\u2019s Association. 2004. Accessed December 29, 2025. https:\/\/www.abstractsonline.com\/viewer\/viewAbstract.asp?CKey=3E7803E4-DCCE-4F90-B692-3551119FB711&MKey=F38908E2-C78B-40E5-B4F4-9817BF853BD1&AKey=50E1744A-0C52-45B2-BF85-2A798BF24E02&SKey=BD4CCC85-1979-4B23-AE35-553338449AD1"},{"key":"zoi260105r38","unstructured":"A long-term extension study evaluating the safety and tolerability of BID and QD administration of memantine in patients with mild to moderate dementia of the Alzheimer\u2019s type-phase C. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/42139?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r39","unstructured":"A long-term extension study evaluating the safety and tolerability of BID and QD administration of memantine in patients with mild to moderate dementia of the Alzheimer\u2019s type-phase D. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/60890?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r41","unstructured":"A long-term extension study evaluating the safety and tolerability of four memantine dosing regimens in patients with moderate to severe dementia of the Alzheimer\u2019s type - phases A and B. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/41817?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r42","unstructured":"A long-term extension study evaluating the safety and tolerability of four memantine dosing regimens in patients with moderate to severe dementia of the Alzheimer\u2019s type- phase C. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/41862?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r45","unstructured":"A multicenter, randomized, double-blind placebo-controlled, flexible-dose study of aripiprazole in the treatment of institutionalized patients with psychosis associated with dementia of the Alzheimer\u2019s type (extension phase of protocol CN138005). Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/65044?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r46","unstructured":"BioXcel Therapeutics Inc. A multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of PRN dosing of BXCL501 over a 12 week period in subjects with agitation associated with dementia. 2023. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05271552"},{"key":"zoi260105r47","unstructured":"Eli Lilly and Company. A phase 3, open-label, parallel-group, 2-arm study to investigate amyloid plaque clearance with donanemab compared with aducanumab-avwa in patients with early symptomatic Alzheimer\u2019s disease. 2024. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05108922"},{"key":"zoi260105r48","unstructured":"A phase iii \/ pivotal study of rivastigmine, TDS for Alzheimer. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/140656?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r49","unstructured":"A phase III study of ABP-124 for Alzheimer\u2019s disease. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/4223?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r52","unstructured":"Forest Laboratories. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in non-institutionalized agitated patients with moderate to severe Alzheimer\u2019s disease. 2012. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT00097916"},{"key":"zoi260105r53","unstructured":"A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer\u2019s type, with a long-term, open-label extension study - phase A. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/52774?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r54","unstructured":"A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer\u2019s type, with a long-term, open-label extension study - phase B. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/52771?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r63","unstructured":"Forest Laboratories. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of neramexane monotherapy in patients with moderate to severe dementia of the Alzheimer\u2019s type. 2012. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT00090116"},{"key":"zoi260105r64","unstructured":"A randomized, parallel-group pilot study to evaluate the brain effects and efficacy of Exelon compared to Aricept in patients with Alzheimer\u2019s disease with an optional 12 month adjunctive Namenda extension. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/13558?qId=beb7c5ac-5632-4c1e-b0db-b0db3e08f911"},{"key":"zoi260105r65","unstructured":"A randomized, parallel-group study to evaluate the efficacy of Trileptal compared to Risperdal in patients with Alzheimer\u2019s dementia. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/13870?qId=beb7c5ac-5632-4c1e-b0db-b0db3e08f911"},{"key":"zoi260105r68","unstructured":"An evaluation of the long-term safety and efficacy of neramexane in patients with moderate to severe dementia of the Alzheimer\u2019s type. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/13552?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r69","unstructured":"Conference abstract. An open-label evaluation of the safety of memantine in patients with moderate-to-severe dementia of the Alzheimer\u2019s type. Annual American Academy of Neurology Meeting. 2010. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/34964?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r71","unstructured":"Small? G. Anti-inflammation in AD: PET imaging supplement. 2020. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT00065169"},{"key":"zoi260105r73","unstructured":"BioVie. BioVie announces completion of last patient treatment visit in phase 3 trial of NE3107 in mild to moderate Alzheimer\u2019s disease - BioSpace. Accessed December 29, 2025. https:\/\/www.biospace.com\/biovie-announces-completion-of-last-patient-treatment-visit-in-phase-3-trial-of-ne3107-in-mild-to-moderate-alzheimer-s-disease"},{"key":"zoi260105r80","unstructured":"Double-blind, placebo-controlled evaluation of the safety and efficacy of neramexane in patients with moderate to severe dementia of the Alzheimer\u2019s disease. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/30231?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r86","unstructured":"Alzheimer\u2019s Association. Galantamine in the treatment of moderate to advanced Alzheimer\u2019s disease: clinical and pharmacoeconomic outcomes in the assisted living environment. Alzheimer\u2019s Association. Accessed December 29, 2025. http:\/\/www.abstractsonline.com\/viewer\/viewAbstract.asp?CKey=8A34B71C-6048-46DE-AA34-94962AC33502&MKey=F38908E2-C78B-40E5-B4F4-9817BF853BD1&AKey=50E1744A-0C52-45B2-BF85-2A798BF24E02&SKey=BD4CCC85-1979-4B23-AE35-553338449AD1"},{"key":"zoi260105r93","unstructured":"Haley? AP. Mechanisms of insulin facilitation of memory. 2014. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT01145482"},{"key":"zoi260105r99","unstructured":"Open label study assessing the safety and efficacy of combined donepezil plus quetiapine in the treatment of agitated demented nursing home patients. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/42145?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r106","unstructured":"Phase III study of citicoline for Alzheimer\u2019s disease. Trialtrove. Accessed April 21, 2023. https:\/\/citeline.informa.com\/trials\/details\/14877?qId=b0a059c5-c397-4a4d-911a-d3ad0b8650fe"},{"key":"zoi260105r107","unstructured":"Johnson & Johnson Pharmaceutical Research & Development, LLC. Placebo-controlled evaluation of galantamine in the treatment of Alzheimer\u2019s disease: a cardiac safety study. 2011. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT00309725"},{"key":"zoi260105r114","unstructured":"Conference abstract. Safety, tolerability, and caregiver\u2019s impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer\u2019s disease. Alzheimer\u2019s Association. 2004. Accessed December 29, 2025. https:\/\/www.abstractsonline.com\/viewer\/viewAbstract.asp?CKey=B7A0303E-9EBF-40EE-AAD0-58297117B183&MKey=F38908E2-C78B-40E5-B4F4-9817BF853BD1&AKey=50E1744A-0C52-45B2-BF85-2A798BF24E02&SKey=BD4CCC85-1979-4B23-AE35-553338449AD127"},{"key":"zoi260105r116","unstructured":"Yesavage? JA. The effect of memantine on brain structure and chemistry in Alzheimer\u2019s disease patients: a randomized, placebo-controlled, 52-week clinical trial. 2017. Accessed December 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT00255086"},{"key":"zoi260105r118","unstructured":"Racial and ethnic categories and definitions for NIH diversity programs and for other reporting purposes: notice number: NOT-OD-15-089. U.S. National Institutes of Health. April 8, 2015. Accessed December 28, 2025. https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-15-089.html"},{"key":"zoi260105r120","unstructured":"Collection of race and ethnicity data in clinical trials and clinical studies for FDA-regulated medical products. U.S. Food and Drug Administration. January 2024. Accessed December 28, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical"},{"key":"zoi260105r121","unstructured":"Revision: NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research: Notice Number: NOT-OD-25-131: U.S. National Institutes of Health. July 17, 2025. Accessed December 28, 2025. https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/NOT-OD-25-131.html"},{"key":"zoi260105r122","unstructured":"What updates to OMB\u2019s race\/ethnicity standards mean for the Census Bureau. US Census Bureau. Accessed December 29, 2025. https:\/\/www.census.gov\/newsroom\/blogs\/random-samplings\/2024\/04\/updates-race-ethnicity-standards.html"},{"key":"zoi260105r137","unstructured":"ENACT Act. Alzheimer\u2019s Impact Movement. Accessed December 28, 2025. https:\/\/alzimpact.org\/enact"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847029\/lin_2026_oi_260105_1774025012.50553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:30:43Z","timestamp":1774625443000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847029"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.2427","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}